Pharmacologic interventions in postmenopausal osteoporosis: Clinical guidelines;Leitfaden zur medikamentösen therapie der postmenopausalen osteoporose

Wiener Medizinische Wochenschrift

Volumn 152, Issue 23-24, 2002, Pages 596-612

  Dimai, H P ^a   Pietschmann, P ^b   Resch, H ^b   Leb, G ^b   Klaushofer, K ^b  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b NONE

Author keywords

Evidence based medicine; Guidelines; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN DERIVATIVE; CALCIUM; ELCATONIN; ESTROGEN; ETIDRONIC ACID; FLUORIDE; FLUORIDE SODIUM; FLUOROPHOSPHATE; NANDROLONE DECANOATE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TIBOLONE; VITAMIN D;

ARTICLE; BONE FRAGILITY; BONE MASS; BONE STRUCTURE; CALCIUM DEFICIENCY; DRUG EFFECT; DRUG EFFICACY; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESPAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

EID: 0036950134     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-258x.2002.d01-16.x     Document Type: Article

References (178)

1. Adami S, Zamberlan N: Adverse effects of bisphosphonates: a comparative review. Drug Safety 1996:14:158-170.
2. Aloia JF, Cohn SH, Vaswani A, Yeh JK, Yen K, Ellis K: Risk factors for postmenopausal osteoporosis. Am J Med 1985:78:95-100.
3. Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn S: Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988:84:401-408.
4. American Association of Clinical Endocrinologists. 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocrine Pract 2001;4:294-312.
5. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD: Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 2002:287:847-857.
6. Berning B, Kuijk CV, Kuiper JW, Bennink HJ, Kicovic PM, Fauser BC: Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996;19:395-399.
7. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C. Christiansen C: Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-2422.
8. Bjarnason NH, Bjarnason K, Hassager C, Christiansen C: The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997:20:151-155.
9. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
10. Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O: An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001:12:519-528.
11. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (FIT Research Group): Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
12. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier JP, Miler SS, Mulloy AL, Recker R, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85:720-726.
13. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD. Bolognese MA, Li Z, Balske A, Lindsay R: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;30:(epub ahead of print).
14. Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH: Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 1997;12:6-15.
15. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR: Estrogen replacement therapy and fractures in older women, Study of Osteoporotic Fractures Research Group. Ann Int Med 1995;122:9-16.
16. Chambers TJ, Magnus CJ: Calcitonin alters behaviour of isolated osteoclasts: J Pathol 1982:136:27-39.
17. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ: Effect of Kalzium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-1082.
18. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ: Vitamin D3 and Kalzium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-1642.
19. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ: Combined Kalzium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalayos II Study. Osteoporos Int 2002;13:257-264.
20. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (PROOF Study Group): A randomized trial of nasal spray salmon calcitonin in postmenopausal women with etsablished osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000;109:267-276.
21. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
22. Compston JE, Watts NB: Combination therapy for postmenopausal osteoporosis. Clin Endocrinol 2002;56:565-569.
23. Consensus Development Conference: Prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107-110.
24. Cranney A, Guyatt G, Krolicki N Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G: A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis, Osteoporosis Research Advisory Group. Osteoporos Int 2001;12:140-151.
25. Cranney A, Welch V, Adachi JD, Guyatt G, Krolicki N, Griffith L, Shea B, Tugwell P, Wells G: Etidronate for treating and preventing postmenopausal osteoporosis (Cochrane Review). Cochrane Database Syst Rev 2001;4:CD003 376.
26. Cumming RG, Nevitt MC: Kalzium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997:12:1321-1329.
27. Cummings SR: The paradox of small changes in bone density and reductions in risk of fracture with raloxifene. Ann N Y Acad Sci 2001;949:198-201.
28. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial, JAMA 1998;280:2077-2082.
29. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-289.
30. Cummings SR, Melton LJ III: Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767.
31. Dawson-Hughes B, Dalla GE, Krall EA, Harris S, Sokoll LJ, Falconer J: Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Ann Int Med 1991;115:505-512.
32. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum SA: A controlled trial of the effect of Kalzium supplementatin on bone density in postmenopausal women. N Engl J Med 1990;323:878-883.
33. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of Kalzium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676.
34. Dawson-Hughes B, Hams SS, Krall EA, Dallal GE, Falconer G, Green CL: Rates of bone loss in postmenopausal women randomly assigned to to one of two dosages of vitamin D. Am J Clin Nutr 1995;61:1140-1145.
35. De Aoysio D, Pansini F, Campobasso C, Zanotti L, Abbruzzese AD, Mauloni M, Bottiglioni F: Effects of cyclic therapy with intranasal carbocalcitonin in healthy spontaneous postmenopausal women. Clin Exp Obstet Gynecol 1996;23(2):87-93.
36. Delmas PD: Treatment of postmenopausal osteporosis. Lancet 2002;359:2018-2026.
37. Devogelaer JP, Broell H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W: Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in post-menopausal women with osteoporosis. Bone 1996;18:141-150.
38. Dure-Smith BA, Kraenzlin ME, Farley SM, Libanati CR, Schulz EE, Baylink DJ: Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action. Calcif Tissue Int 1991;49(Suppl):64-72.
39. Eanes ED: The effect of Fluoride on bone mineral apatite. Metab Bone Dis Relat Res 1979;2:3-10.
40. Eisman JA: Vitamin D metabolism. In: GR Mundy and TJ Martin (eds): Physiology and Pharmacology of Bone, New York-Berlin-Heidelberg, Springer Verlag, 1993, pp 333-375.
41. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB: Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617-2624.
42. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glueer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture: risk in postmenopausal women with osteoporosisi treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
43. Farley JR, Tarbaux N, Baylink DJ: Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 1983;222:330-332.
44. Farley J, Dimai HP, Stilt-Coffing B, Farley P, Pham T, Mohan S: Calcitonin increases the concentration of insulin-like growth factors in serum-free cultures of human osteoblast-line cells, Calcif Tissue Int 2000;67:247-254.
45. Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W [Fosamax International Trial (FOSIT) Study Group]: Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. Maturitas 1998;31:35-44.
46. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM: Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-1623.
47. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-138.
48. Fleisch H: Bisphosphonate bel Knochenerkrankungen. Bern-Göttingen-Toronto, Verlag Hans Huber, 1998.
49. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY: Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000;85:1895-1900.
50. Fratzl P, Roschger P, Eschberger J, Abendroth B, Klaushofer K: Abnormal bone mineralization after flouride treatment in osteoporosis: a small-angle x-ray scattering study. J Bone Miner Res 1994;9:1541-1549.
51. Frost HM: Should future risk-of-fracture analyses include another major risk factor? The case for falls. J Clin Densitom 2001;4:381-383.
52. Gallagher JC, Baylink DJ, Freeman R, McClung M: Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-4726.
53. Gallagher JC, Goldgar D: Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Int Med 1990;113:649-655.
54. Gallagher JC, Jerpbak CM, Jee WS, Johnson KA, DeLuca HF, Riggs BL: 1,25-dihydroxyvitamin D3: short- and long-term effects on bone and Kalzium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci USA 1982;79:3325-3329.
55. Gambacciani M, Spinetti A, Taponeco F, Piaggesi L, Cappagli B, Ciaponi M, Rovati LC, Genazzani AR: Treatment of postmenopausal vertebral osteopenia with monofluorphosphate: a long-term Kalzium-controlled study. Osteoporos Int 1995;5:467-471.
56. Gennari C, Agnusdei D, Camporeale A: Long-term treatment with calcitonin in osteoporosis. Horm Metab Res 1993;25:484-485.
57. Geusens P: Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheumatol 1995;14(Suppl 3):32-39.
58. Geusens P, Dequeker J: Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent Kalzium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1986;1:347-357.
59. Gibbs CJ, Aaron JE, Peacock M: Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J 1986;292:1227-1229.
60. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor: Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Int Med 2002;162:665-672.
61. Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallak RW, Dhaliwal SS, Stuckey BGA, Drury P, Jones CE, Faulkner DL, Kent GN, Bhagat CI, Nicholson GC, Jamrozik K: A randomized trial of sodium fluoride (60 mg) ± estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 2002;13:158-170.
62. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G: Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000;11:727-738.
63. Halasy-Nagy JM, Rodan GA, Reszka AA: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001;29:553-559.
64. Harbour R, Miller J for the Scottish Intercollegiate Guidelines Network Grading Review Group: A new system for grading recommendations in evidence based guidelines. Brit Med J 2001;323:334-336.
65. Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett AH Jr, Baylink DJ, Crusan CE, Chines AA: Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86:1890-1897.
66. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, (Vertebral Efficacy With Risedronate Therapy [VERT] Study Group). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-1352.
67. rd: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-567.
68. Heany RP, Zizic TM, Fogelman I, Olssszynski WP, Geusens P, Kasibhata C, Alsayed N, Isaia G, Davie MW, Chesnut III CH: Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002;13:501-505.
69. Heikinheimo RJ, Inkovaara JA, Harju EJ, Haavisto MV, Kaarela RH, Kataja JM, Kokko AM, Kolho LA, Rajala SA: Annual injections of vitamin D and fractures of aged bones. Calcif Tissue Int 1992;541:105-110.
70. Hochberg MC. Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD: Changes in bone density and turnover explain the reduction in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-1592.
71. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D: Larger increases in bone mineral density during alendronate are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999;42:1246-1254.
72. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M. Yates AJ (Early Postmenopausal Intervention Cohort Study Group): Prevention of bone loss with alendronate in post-menopausal women under 60 years of age. N Engl J Med 1998;338:485-492.
73. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
74. Janssen HC, Samson MM, Verhaar HJ: Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002;75:611-615.
75. Johnell O, Scheele WH, Lu Y, Reginsetr JY, Need AG, Seeman E: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-994.
76. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.
77. Kanis JA: The use of Kalzium in the management of osteoporosis. Bone 1999;24:279-290.
78. Kanis JA and the World Health Organisation Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. Osteoporosis Int 1994;4:368-381.
79. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D: Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997;7:390-406.
80. Kanis JA, Geusens P, Christiansen C: Guidelines for clinical trials in osteoporosis: A position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int 1991;1:182-188.
81. Kanis JA, Glüer CC for the Committee of Scientific Advisors, International Osteoporosis Foundation: An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporosis Int 2000;11:192-202.
82. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C. Jonsson B: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-995.
83. Kanis JA, WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994;4:368-381.
84. Karpf DB. Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC 2nd, Hirsch LJ, Oppenheimer L, Thompson D (Alendronate Osteoporosis Treatment Study Groups): Prevention of nonvertebral fractures by alendronate: a meta-analysis. JAMA 1997;277:1159-1164.
85. Khan SA, de Geus C, Holroyd B, Russel AS: Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 2001;161:1309-1312.
86. Kleerekoper M: Fluoride and the skeleton. Crit Rev Clin Lab Sci 1996;33:139-161.
87. Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991;1:155-161.
88. Kloosterboer HJ: Tibolone: a steroid with a tissue-specific mode of action. Steroid Biochem Mol Biol 2001;76:231-238.
89. Klotzbuecher CM, Ross PD, Landsman PB, Abbot TA III, Berger M: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739.
90. Komulainen MH, Kroger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Saarkoski S: HRT and Vitamin D in prevention of nonvertebral fractures in postmenopausal women; a 5-year randomized trial. Maturitas 1998;31:45-54.
91. Liberman UA, Weiss SR, Broell J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M: (Alendronate Phase III Osteoporosis Treatment Study Group): Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443.
92. Lindsay R: The lack of effect of progestagen on bone. J Reprod Med 1999;44(Suppl2):215-220.
93. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST. Reagan JE, Liss CL, Melton ME, Byrnes CA: Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076-3081.
94. Lips P: Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Rev 2001;22:477-501.
95. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM: Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled trial. Ann Intern Med 1996;124:400-406.
96. Looker AC, Bauer DC, Chesnut III CH, Gundberg CM, Hochberg MC, Klee G. Kleerekoper M, Watts NB, Bell NH: Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000;11:467-480.
97. Lowe CE, Depew WT, Vanner SJ. Paterson WG, Meddings JB: Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000;95:634-640.
98. Lozano-Tonkin C, Gracia A, Jareno J, Mercadal J: Double-blind study on the efficacy of long-term intermittent nasal elcatonin in recent postmenopausal women. An Med Interna 2000;17:399-405.
99. Luckman SP, Hughes DE, Coxon FP, Russel RG, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
100. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotwicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 1992;117:1-9.
101. Lund BJ, Sorensen OH, Lund BI, Agner E: Serum 1.25-dihydroxyvitamin D in normal subjects and in patients with postmenopausal osteopenia. Influence of age, renal function and oestrogen therapy. Horm Metab Res 1982;14:271-274.
102. Lyritis GP, Androulakis C, Magiasis B, Charalambaki Z, Tsakalakos N: Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. A double-blind clinical trial. Bone Miner 1994;27:209-217.
103. Lyritis GP, loannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaiannou N, Kaloudis J, Galanos A: Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, plazebo-controlled clinical study. Clin J Pain 1999;15:284-289.
104. MacIntyre I, Stevenson JC, Whithead MI, Wimilawansa SJ, Banks LM, Healy MJ: Calcitonin for prevebtion of postmenopausal bone loss. Lancet 1988;1:900-902.
105. Mackerras D, Lumley T: First- and second-year effects in trials of Kalzium supplementation on the loss of bone density in postmenopausal women. Bone 1997;21:527-533.
106. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Keleghan J: The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999;14:1583-1595.
107. Marcus R, Wong Mayme, Heath H, Stock JL: Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002;23:16-37.
108. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD: Early effects of raloxifene on clinical vertebral fractures at 12 months in post-menopausal women with osteoporosis. Arch Int Med 2002;162:1140-1143.
109. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:613-620.
110. Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G: Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986;38:3-8.
111. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (Hip Intervention Program Study Group): Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340.
112. McKenna MJ, Freaney R: Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D, Osteoporos Int 1998;8 (Suppl):3-6.
113. Melton LJ III: How many women have osteoporosis now? J Bone Miner Res 1995;10:175-177.
114. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X: Fluoride salts are no better at preventing vertebral fractures than Kalzium-vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 1998;8:4-12
115. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese CL, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-2066.
116. Miller PD, Barran DT, Bilezikian JT, Greenspan SL, Lindsay R, Riggs BL, Watts NB: Practical clinical applications of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 1999;2:323-342.
117. Mitlak BH, Cohen FJ: Selective estrogen receptor modulators: a look ahead. Drugs 1999;57:653-663.
118. Mundy GR, Guise TA: Hormonal control of Kalzium homeostasis. Clin Chem 1999;45:1347-1352.
119. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckmann EM: Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979;53:277-281.
120. Need AG, Durbridge TC, Nordin BE: Anabolic steroids in postmenopausal osteoporosis. Wien Med Wochenschr 1993;143:392-395.
121. Neele SJM, Evertz R, Valk-De Roo G, Roos JC, Netelenbos JC: Effect of 1 year of discontinuation of Raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603.
122. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1341.
123. Norman AW: Receptors for 1alpha, 25(OH)2D3: past, present, and future. J Bone Miner Res 1998;13:1360-1369.
124. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR: Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Int Med 1995;123:401-408.
125. Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG: Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas 1993;17:211-219.
126. Petiti DB: Hormone replacement therapy for prevention. More evidence, more pessimism. JAMA 2002;288:99-101
127. Pfeifer M, Begerow B, Minne HW: Vitamin D and muscle function. Osteoporos Int 2002;13:187-194.
128. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C: Effects of a short-term vitamin D and Kalzium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15:1113-1118.
129. Phillips B, Ball C, Sackett D, Haynes B, Straus S, McAlister F: Levels of Evidence 2002. The Centre for Evidence Based Medicine. Oxford-UK; www.eboncall.co.uk/content/levels.html
130. Pols HA, Felsenberg D, Hanley DA Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B: (Fosamax International Trial Study Group): Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in post-menopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999;9:461-468.
131. Quigley ME, Martin PL, Burnier AM, Brooks P: Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987;156:1516-1523.
132. Ravn P, Weiss SR, Rodriguez-Portales JARodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE (Alendronate Osteoporosis Prevention Study Group): Alendronate in early postmenopausal women: effects on bone mass during long -term treatment and after withdrawal. J Clin Endocrinol Metab 2000;85:1492-1497.
133. Recker RR, Davies KM, Dowd RM, Heaney RP: The effect of lowdose continous estrogen and progesterone therapy with Kalzium and vitamin-D on bone in elderly women: a randomized, controlled trial. Ann Int Med 1999;130:897-904.
134. Recker RR, Hinders S, Davis KM, Heaney RP, Stegman MR: Correcting Kalzium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996;11:1961-1966.
135. Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P: 1-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;1481-1483.
136. Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P: A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and Kalzium. Eur J Clin Invest 1994;24:565-569.
137. Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C: The effect of sodium monofluorophosphate plus Kalzium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998;129:1-8.
138. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R Vertebral Efficacy with Risedronate Therapy [VERT] Study Group): Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
139. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ: Long-term effects of Kalzium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med;1995;98:331-335.
140. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier P: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002 Feb 28;346:653-661.
141. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F: Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 1992 Feb;16:131-138.
142. Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez de Buergo M; Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis-treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995;56:181-185.
143. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ III: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-809.
144. Riggs BL, O'Fallon WM, Lane A, Hodgson SF, Wahner HW, Muhs J, Chao E, Melton LJ III: Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 1994;9:265-275.
145. Rodriguez-Martinez MA, Garcia-Cohen EC: Role of Kalzium and vitamin D in the prevention and treatment of osteoporosis. Pharmacol Ther 2002;93:37-49.
146. Rovetta G, Monteforte P, Balestra V: Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res 2000;26:25-30.
147. Royal College of Physicians, Bone and Tooth Society: Osteoporosis. Clinical Guidelines for prevention and treatment. Update on pharmacological interventions and algorithm for Management. London, Royal College of Physicians; www.rcplondon.ac.uk.
148. Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS: Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Int Med 2001;161:2325-2333.
149. Russel RG, Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106.
150. Sacket DC: Rules of evidence and clinical recommendation on the use of antithrombotic agents. Chest 1989;1986:2S-3S.
151. Schnitzer T, Bone HG, Crepaldl G, Adami S, McClung M, Kiel D, Felsenberg D, Reeker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd. Kaur A, Thompson DE, Yates J, Orloff JJ: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging 2000;12:1-12.
152. Sebert JL, Richard P, Mennecier I, Bisset JP, Loeb G: Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study. Osteoporos Int 1995;5:108-114.
153. Shikari M, Kushida K, Yamazaki K, Nagai T, Inoue T, Orimo H: Effects of 2 years' treatment with 1-alpha-hydroxyvitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 1996;43:211-220.
154. Shorr E, Carter AC: The usefulness of strontium as an adjuvant to Kalzium in the remineralization of the skeleton in man. Bull Hosp Jt Dis Orthop Inst 1952;13:59-66.
155. Skoryna SC: Effects of oral supplementation with stable strontium. Can Med Assoc J 1981;125:703-712.
156. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Institute of Medicine: Dietary Reference Intakes: Kalzium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington DC, National Academy Press, 1997.
157. nd: Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-297.
158. Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH: Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996;23:1560-1564.
159. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-1271.
160. The National Institute of Health (NIH): Optimal Kalzium intake. Nutrition 1999;11:409-417.
161. The North American Menopause Society: Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 2002;9:84-101.
162. The North American Menopause Society; The role of Kalzium in peri- and postmenopausal women: consensus opinion of the North American Menopause Society. 2001;8:84-95.
163. The Women's Health Initiative Study Group: Design of the Women's Health Initiiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
164. The writing group for the PEPI: Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;276:1389-1396.
165. Tilyard MW, Spears GF, Thomson J, Dovey S: Treatment of postmenopausal osteoporosis with calcitriol or Kalzium. N Engl J Med 1992;326:406-408.
166. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (Phase III Osteoporosis Treatment Study Group): Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-3115.
167. Torgerson DJ, Bell-Syer EM: Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. JAMA 2001;285:2891-2897.
168. Turner RT, Riggs BL, Spelsberg TC: Skeletal effects of estrogen. Endocr Rev 1994;15:275-300.
169. Valtola A, Honkanen R, Kroger H, Tuppurainen M, Saarikoski S, Alhava E: Lifestyle and other factors predict ankle fractures in perimenopausal women: a population-based prospective cohort study. Bone 2002;30:238-242.
170. van der Voort DJ, Dinant GJ, Rinkens PE, van der Voort-Duindam CJ, van Wersch JW, Geusens PP: Construction of an algorithm for quick detection of patients with low bone mineral density and its applicability in daily general practice. J Clin Epidemiol 2000;53:1095-1103.
171. Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-236.
172. rd, Yanover MJ: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
173. Weiss SR, Ellman H, Dolker M: A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999;94:330-336.
174. Wimalawansa SJ: A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-226.
175. Wimalawansa SJ: Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995;99:36-42.
176. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women' Health Initiative randomized controlled trial. JAMA 2002;288:312-333.
177. Yoshikawa S, Shiba M, Hoshino T, Igarashi M, Orimo H, Sakuma A, Tsuyama N: Effect of eel calcitonin derivate elcatonin in osteoporosis. Nippon Sei Ga Za 1983;57:1717-1728.
178. Yoshimura M: Analgesic mechanism of calcitonin. J Bone Miner Metab 2000;18:230-233.